GlassScriptPhysician profile
Narien K Grover
NPI 1104850734
$8,512.56
in general payments reported to CMS, 2019-2025
38 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $1,357 · 2021: $3,286 · 2022: $1,369 · 2023: $915 · 2024: $563 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,455.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Welch Allyn | $1,092.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $828.94 | 2019-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $723.13 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $597.01 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $574.35 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amarin Pharma, INC. | $388.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.24 | 2019-2024 | Jardiance |
| Abbvie INC. | $251.96 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $241.81 | 2019-2023 | |
| Esperion Therapeutics, INC. | $202.98 | 2020-2024 | Nexletol |
| Glaxosmithkline, LLC. | $197.21 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $185.58 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.95 | 2021-2023 | |
| Exact Sciences Corporation | $129.18 | 2023-2024 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narien Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.